The fourth in a series of articles by RN Collins about legal issues, concepts and psychedelics
Access, Equity & the Future of Psychedelic Regulation
In 2022, an Indigenous-led cooperative from the Brazilian Amazon arrived at a World Intellectual Property Organization (WIPO) meeting on traditional knowledge in Geneva, only to be denied entry for lack of costly accreditation and legal counsel—while pharmaceutical representatives with multimillion-dollar backers entered effortlessly.
This imbalance is not an isolated embarrassment; it encapsulates the emerging psychedelic economy: the communities whose ancestral knowledge underpins much of the industry are often excluded from decision-making spaces (Nagoya Protocol, 2010; UNDRIP, Art. 31). Fast forward to August 2025: in Denver, a wellness clinic charges over USD 3,500 per three-session psilocybin program under Colorado’s Natural Medicine Health Act implementation, while in the rural South, Black and Latinx individuals continue to face arrest under federal law for possession of the same compound (Sentencing Project, 2023).
Oregon’s Psilocybin Services Act offers licensed sessions under Oregon Health Authority rules requiring client preparation and integration sessions (OHA, 2023, OAR 333-333-5050), but—as of 2025—contains no explicit racial equity mandates in licensing or service delivery. Colorado’s Department of Regulatory Agencies has issued memos clarifying broader exemptions for certain natural medicine practices (CO DORA, 2024), yet equity-focused participation targets remain voluntary.
These snapshots reveal a widening chasm between legality and lived access. Even as human rights instruments like the International Covenant on Economic, Social and Cultural Rights (ICESCR) affirm the right to participate in cultural life (Art. 15), and the Nagoya Protocol requires equitable benefit-sharing, the structures governing psychedelic legalization often privilege wealth and corporate power (Crenshaw, 1989; Carbado, 2011; Raval & Kersh, 2022). This article interrogates whether legalization can be harnessed for justice—or whether, without intentional design, it will reproduce the same inequities that marked cannabis commercialization and decades of drug-war enforcement.
Full Article
